Description: TVAX Biomedical, Inc. is a biotechnology company currently performing phase II clinical trials to test a unique natural cancer immunotherapy as a treatment for brain cancer.
cancer (3381) brain cancer (52) carcinoma (30) alternative cancer treatment (26) cancer immunotherapy (11) cancer vaccine (7) astrocytoma (7) cancer clinical trial (3) adoptive cell therapy (2) cancer cellular therapy (1)
Careers | Contact us About Us Management Board of Directors Scientific Advisors Intellectual Property The TVAX Platform Scientific Rationale Clinical Data Manufacturing Support References TVI-Brain-1 Clinical Data Pipeline TVI-Kidney-1 Additional Programs Consumer Resources News & Events In the News Events Calendar Animal Health Home
TVAX Biomedical is developing a paradigm-shifting cancer treatment that offers the promise of improved clinical outcomes and low toxicity and the potential for fundamentally changing the way cancer is treated.
TVAX Immunotherapy® is a unique personalized “killer” T cell treatment. TVAX Immunotherapy employs the natural ability of T cells to kill cancer cells. Activated “killer” T cells have demonstrated the ability to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. TVAX is distinct from other cancer immunotherapy companies in its use of ex vivo-activated cancer antigen-specific “killer” T cells as the active agent in its treatment. To lea